Report Highlights
Did you know that 45K+ diversion cases have been opened due to ControlCheck alerts?
Source: Bluesight
Dive into RXinsider’s latest company overview report on Bluesight:
- Learn how Bluesight operates its business and what major products and services are offered
- Explore Bluesight’s 2025 and 2026 strategic initiatives, M&A timeline, current GPO contracts, and more!
The spirit of RXinsider’s “Company Overview” reports is to educate pharmacists, pharmacy technicians, and other pharmacy professionals on our industry’s largest companies by simplifying, organizing, and presenting publicly available information in a consistent and organized format. The objective of this report is to educate Pharmacy500 professionals, pharmacy leadership, and other stakeholders on major players in the industry.
Bluesight Defines Itself in the Following Way:
“Bluesight enables hospital operations with intelligence that simplifies inventory management, procurement, and compliance. Through its suite of industry-leading, AI-powered solutions, Bluesight ensures that health systems protect every patient and optimize every dollar. Over 3,000 United States and Canadian hospitals rely on Bluesight every day.”
For more information, please visit the Bluesight website.
Executive Snapshot Highlights
- 266M medication transactions tracked by ControlCheck
- 100% KitCheck restocking accuracy in kits and trays
- 42 seconds average response time of Prism Assistant
History and Timeline Highlights
2011: Bluesight was founded with the invention of the RFID solution, KitCheck
2012: Bluesight gained its first two customers: The University of Maryland Medical Center and NYU Langone
2015: Bluesight began to offer pre-tagged 503B compounded drugs
2017: Bluesight launched ControlCheck, an AI-powered drug diversion monitoring solution
2020: Bluesight launched CostCheck, which helps optimize drug spending
2022: Bluesight launched the first-ever Medication Intelligence Summit
2023: Thoma Bravo announced a strategic growth investment in Bluesight to support the company’s acquisition of Medacist
2024: Bluesight reached 2,000+ hospital customers
2025: Bluesight reached 3,000+ hospital customers
2026: Bluesight launched Prism, the first AI platform built specifically for hospital pharmacy and compliance teams
Company Overview Reports
Company Overview Reports are training aids developed for general education purposes and are biased toward presenting the information we feel our pharmacy audience would find most relevant. These reports may be incomplete, are general in nature, and should not be used for making investing decisions.
The Bluesight Report is independent and has not been funded by Bluesight employees or company representatives. All information in the following report is publicly available.
Pharmacy500 Market Intelligence Reports
The objective of RXinsider’s weekly Market Intelligence Reports is to educate Pharmacy500 professionals, pharmacy leadership, and other stakeholders on key trends within the supply chain as it relates to the pharmacy industry.
Learn more about RXinsider’s weekly Market Intelligence Reports on our website: RXinsider.com/pharmacy_market_intelligence
Having Trouble Accessing Reports?
Request a two-week trial here.
